Pacira BioSciences, Inc. (PCRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) has a cash flow conversion efficiency ratio of 0.039x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($25.68 Million) by net assets ($653.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pacira BioSciences, Inc. balance sheet quality to measure how much of total assets are equity-financed.
Pacira BioSciences, Inc. - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PCRX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Pacira BioSciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pacira BioSciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CSSC Offshore & Marine Engineering (Group) Co Ltd
F:GSZ
|
-0.130x |
|
Jiangsu Maixinlin Aviation Science & Technology Corp. A
SHG:688685
|
0.244x |
|
NB Bancorp, Inc. Common Stock
NASDAQ:NBBK
|
0.028x |
|
Shandong Laiwu Jinlei Wind Power Technology Co Ltd
SHE:300443
|
0.014x |
|
Altri SGPS SA
LS:ALTR
|
0.074x |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
0.022x |
|
Beijing Sanyuan Foods Co Ltd
SHG:600429
|
0.037x |
|
Qingdao Port International Co. Ltd
F:0QP
|
0.037x |
Annual Cash Flow Conversion Efficiency for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual cash flow conversion efficiency of Pacira BioSciences, Inc. from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Pacira BioSciences, Inc. (PCRX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $693.11 Million | $151.99 Million | 0.219x | -9.88% |
| 2024-12-31 | $778.35 Million | $189.39 Million | 0.243x | +36.90% |
| 2023-12-31 | $870.13 Million | $154.65 Million | 0.178x | -5.18% |
| 2022-12-31 | $775.01 Million | $145.27 Million | 0.187x | +8.91% |
| 2021-12-31 | $730.41 Million | $125.72 Million | 0.172x | +38.46% |
| 2020-12-31 | $619.69 Million | $77.03 Million | 0.124x | -37.43% |
| 2019-12-31 | $354.94 Million | $70.52 Million | 0.199x | +30.59% |
| 2018-12-31 | $321.23 Million | $48.87 Million | 0.152x | +139.07% |
| 2017-12-31 | $279.48 Million | $17.79 Million | 0.064x | -58.35% |
| 2016-12-31 | $218.98 Million | $33.45 Million | 0.153x | +15.06% |
| 2015-12-31 | $218.39 Million | $29.00 Million | 0.133x | -10.78% |
| 2014-12-31 | $171.15 Million | $25.47 Million | 0.149x | +114.20% |
| 2013-12-31 | $41.25 Million | $-43.22 Million | -1.048x | +1.62% |
| 2012-12-31 | $65.86 Million | $-70.13 Million | -1.065x | -65.81% |
| 2011-12-31 | $48.27 Million | $-31.00 Million | -0.642x | -224.89% |
| 2010-12-31 | $-48.38 Million | $-24.88 Million | 0.514x | -43.37% |
| 2009-12-31 | $-22.95 Million | $-20.84 Million | 0.908x | +123.30% |
| 2008-12-31 | $7.49 Million | $-29.19 Million | -3.897x | -- |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more